IMCR
NASDAQImmunocore Holdings plc
News · 26 weeks27+500%
2026-03-012026-08-23
Mix1490d
- Insider6(43%)
- Other3(21%)
- Earnings2(14%)
- SEC Filings2(14%)
- Analyst1(7%)
Latest news
25 items- ANALYSTAnalyst resumed coverage on Immunocore with a new price targetAnalyst resumed coverage of Immunocore with a rating of Overweight and set a new price target of $50.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Immunocore Holdings plcSCHEDULE 13G/A - Immunocore Holdings plc (0001671927) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Immunocore Holdings plcSCHEDULE 13G/A - Immunocore Holdings plc (0001671927) (Subject)
- SECSEC Form 10-Q filed by Immunocore Holdings plc10-Q - Immunocore Holdings plc (0001671927) (Filer)
- SECImmunocore Holdings plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Immunocore Holdings plc (0001671927) (Filer)
- PRImmunocore reports second quarter financial results and provides a business updateImmunocore reports second quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $115.9 million in Q2 2026, growing by 18% year-over-year Enrollment in Phase 3 TEBE-AM trial for previously treated advanced cutaneous melanoma nearing the target of 540 patients – Data could come as early as end of 2026 Oral presentation of five-year overall survival data showing KIMMTRAK doubles likelihood of being alive at five years for patients with HLA-A*02:01 positive metastatic uveal melanoma Promising Phase 1 brenetafusp monotherapy clinical activity in heavily pretreated HLA-A*02:01-positive patients with advanced melanoma, presented at ASCO, supports
- PRImmunocore to report second quarter 2026 financial results and host call on August 6, 2026Immunocore to report second quarter 2026 financial results and host call on August 6, 2026 (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 30 July 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results for the second quarter ended June 30, 2026 on Thursday, August 6, 2026. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) to discuss
- PRImmunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanomaImmunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a 6-month overall survival rate of 87% and disease control rate of 52% in heavily pretreated HLA-A*02:01-positive patients with melanoma Data support selection of 160 mcg dose for the ongoing Phase 3 PRISM-MEL-301 trial in first-line advanced melanoma Clinical benefit was consistent across difficult-to-treat subgroups, including patients with primary PD-1 resistance Brenetafusp was generally well tolerated as monotherapy and in combination with pembrolizumab (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 31 May 2026) Immunocore
- INSIDERSEC Form 4 filed by Director Kaul Siddharth4 - Immunocore Holdings plc (0001671927) (Issuer)
- INSIDERSEC Form 4 filed by Director Pao William4 - Immunocore Holdings plc (0001671927) (Issuer)
- INSIDERSEC Form 4 filed by Director Ratcliffe Peter John4 - Immunocore Holdings plc (0001671927) (Issuer)
- INSIDERSEC Form 4 filed by Director Peterson Kristine4 - Immunocore Holdings plc (0001671927) (Issuer)
- INSIDERSEC Form 4 filed by Director Herbst Roy Steven4 - Immunocore Holdings plc (0001671927) (Issuer)
- INSIDERSEC Form 4 filed by Director Bell John Irving4 - Immunocore Holdings plc (0001671927) (Issuer)
- SECImmunocore Holdings plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Immunocore Holdings plc (0001671927) (Filer)
- SECSEC Form S-8 filed by Immunocore Holdings plcS-8 - Immunocore Holdings plc (0001671927) (Filer)
- SECImmunocore Holdings plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Immunocore Holdings plc (0001671927) (Filer)
- SECSEC Form 10-Q filed by Immunocore Holdings plc10-Q - Immunocore Holdings plc (0001671927) (Filer)
- PRImmunocore reports first quarter financial results and provides a business updateImmunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) Q1 net sales of $106.7 million, growing by 14% year-over-year Oral presentation at AACR: KIMMTRAK doubles likelihood of being alive at five years for patients with HLA-A*02:01 positive metastatic uveal melanoma Cash, cash equivalents and marketable securities of $845 million as of March 31, 2026 (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 6 May 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for
- PRKIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanomaKIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma OS benefit observed across key subgroups, including patients with high tumor burden, elevated LDH, and extrahepatic disease as well as those with best response of progressive disease This is the longest OS follow-up in a randomized trial in metastatic uveal melanoma and for any T cell engager in a solid tumor (OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn., US, 19 April 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicin
- SECSEC Form DEF 14A filed by Immunocore Holdings plcDEF 14A - Immunocore Holdings plc (0001671927) (Filer)
- PRImmunocore to present at the 25th Annual Needham Virtual Healthcare ConferenceImmunocore to present at the 25th Annual Needham Virtual Healthcare Conference (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 06 April 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate in the 25th Annual Needham Virtual Healthcare Conference. 25th Annual Needham Virtual Healthcare Conference Fireside Chat: Monday, April 13, 2026, at 3:00 p.m. EDT The presentation will be webcast li
- PRImmunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meetingImmunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting (OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn., US, 17 March 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will present the five-year overall survival (OS) from the KIMMTRAK (tebentafusp-tebn) Phase 3 trial in previously untreated HLA-A*02:01 positive patients with unresected or metastatic uveal melano
- ANALYSTImmunocore downgraded by Jefferies with a new price targetJefferies downgraded Immunocore from Buy to Hold and set a new price target of $33.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Immunocore Holdings plcSCHEDULE 13G/A - Immunocore Holdings plc (0001671927) (Subject)
IMCR FAQ
7 questionsWhat does Immunocore Holdings plc do?
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with...Where does IMCR stock trade?
Immunocore Holdings plc (IMCR) is listed on NASDAQ.What sector and industry is IMCR in?
Immunocore Holdings plc operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Immunocore Holdings plc go public?
Immunocore Holdings plc (IMCR) completed its IPO in 2021.What are analysts saying about IMCR?
Immunocore Holdings plc has had 8 recent analyst actions on file. The most recent action was from Analyst: Overweight on 2026-08-21. Recent price targets range from $3300.00 to $4800.00.What companies are similar to IMCR?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare IMCR side-by-side with any of them on Quantisnow.How can I track IMCR on Quantisnow?
Quantisnow aggregates Immunocore Holdings plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMCR to receive live email and push alerts on every new disclosure.